

**Mental Health Policy and  
Service Guidance Package**

# IMPROVING ACCESS AND USE OF PSYCHOTROPIC MEDICINES



World Health Organization

## WHO Library Cataloguing-in-Publication Data

Improving access and use of psychotropic medicines.  
(Mental health policy and service guidance package)

1. Psychotropic drugs - supply and distribution
2. Essential drugs - supply and distribution
3. Mental disorders - drug therapy
4. Drug utilization
5. Drug costs

6. Drug and narcotic control - methods

7. Guidelines I. World Health Organization

ISBN 92 4 154641 7

(NLM classification: QV 77.2)

Technical information concerning this publication can be obtained from:

Dr Michelle Funk

*Mental Health Policy and Service Development*

*Department of Mental Health and Substance Abuse*

Dr Hans Hogerzeil and Ms Marthe Everard

*Policy, Access and Rational Use*

*Department of Essential Drugs and Medicines Policy*

World Health Organization

CH-1211, Geneva 27

Switzerland

Tel: +41 22 791 3855

Fax: +41 22 791 4160

E-mail: [funkm@who.int](mailto:funkm@who.int)

© World Health Organization 2005

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in China

## Acknowledgements

---

The Mental Health Policy and Service Guidance Package was produced under the direction of Dr Michelle Funk, Coordinator, Mental Health Policy and Service Development, and was supervised by Dr Benedetto Saraceno, Director, Department of Mental Health and Substance Abuse, World Health Organization.

The World Health Organization expresses its gratitude to Dr Hilbrand Haak, Consultant for Health and Development in the Netherlands for preparing this module.

### **WHO Editorial and technical coordination group:**

---

Ms Marthe Everard, World Health Organization, Headquarters (WHO/HQ), Dr Hans Hogerzeil, (WHO/HQ), Dr Michelle Funk (WHO/HQ) and Dr Benedetto Saraceno (WHO/HQ).

### **Technical assistance:**

---

Dr Jose Bertolote, (WHO/HQ), Ms Natalie Drew (WHO/HQ), Dr José Miguel Caldas de Almeida, WHO Regional Office for the Americas (AMRO), Dr Thérèse Agossou, WHO Regional Office for Africa, (AFRO), Dr Vijay Chandra, WHO Regional Office for South-East Asia, (SEARO), Dr Ahmad Mohit, WHO Regional Office for the Eastern Mediterranean, (EMRO), Dr Wolfgang Rutz, WHO Regional Office for Europe, (EURO), Dr Xiangdong Wang, WHO Regional Office for Western Pacific Region (WPRO) AND Dr Catherine Le Galès-Camus (WHO/HQ).

Dr Crick Lund, University of Cape Town, Observatory, Republic of South Africa, finalized the technical editing of this module.

### **Administrative and secretarial support:**

---

Ms Adeline Loo (WHO/HQ), Mrs Anne Yamada (WHO/HQ) and Mrs Razia Yaseen (WHO/HQ).

Layout and graphic design: 2S ) graphicdesign

Editor: Praveen Bhalla

**WHO also wishes to thank the following people for their expert opinion and technical input to this module:**

<b>Dr Jo B. Asare</b>	Ministry of Health and Psychiatric Hospital, Accra, Ghana
<b>Dr Corrado Barbui</b>	Department of Medicine and Public Health, University of Verona, Italy
<b>Dr Claudina Cayetano</b>	Director, Mental Health Program, Ministry of Health, Belmopan, Belize
<b>Professor Emilio C. Cermignani</b>	Assistant Professor of Pharmacology, Cátedra de Farmacología, La Plata, Argentina
<b>Dr Dolors Capellà Hereu</b>	Servei de Farmacologia Clínica, Barcelona, Spain
<b>Dr Alex Cohen</b>	Department of Social Medicine, Harvard Medical School, Boston, USA
<b>Dr Douma Djibo Maïga</b>	Ministry of Public Health, Niamey, Niger
<b>Professor Helen Herrman</b>	Department of Psychiatry, University of Melbourne, Victoria, Australia
<b>Dr Ahmed Mohamed Heshmat</b>	Ministry of Health and Population, Cairo, Egypt
<b>Dr Lars Jacobsson</b>	Department of Psychiatry, Faculty of Medicine, University of Umea, Sweden
<b>Dr Dale L. Johnson</b>	President, World Fellowship for Schizophrenia and Allied Disorders, Toronto, Ontario, Canada
<b>Dr Nancy Jones</b>	WHO Consultant, Mental Health Planning for Cambodia, Seattle, USA
<b>Professor Zurab I. Kekelidze</b>	Deputy Director, Serbsky National Research Centre for Social and Forensic Psychiatry, Moscow, Russian Federation
<b>Dr Pirkko Lahti</b>	Executive Director, Finnish Mental Health Association, Helsinki, Finland
<b>Dr Richard Laing</b>	Associate Professor, International Health, Boston University School of Public Health, Boston, USA
<b>Dr Philippe Lehmann</b>	Director, Swiss National Health Policy Project, Bern, Switzerland
<b>Dr Itzhak Levav</b>	Adviser on Research, Policy and External Relations, Mental Health Services, Ministry of Health, Jerusalem, Israel
<b>Dr Alberto Minoletti</b>	Director, Mental Health Unit, Ministry of Health, Santiago, Chile
<b>Dr Paul Morgan</b>	SANE, South Melbourne, Victoria, Australia
<b>Dr Eva Ombaka</b>	Ecumenical Pharmaceutical Network, Nairobi, Kenya
<b>Dr Vikram Patel</b>	Sangath Centre, Goa, India
<b>Dr Michael Phillips</b>	Associate Professor, Beijing Hui Long Guan Hospital, Beijing, China
<b>Dr Rampersad Parasram</b>	Principal Medical Officer, Ministry of Health, Port of Spain, Trinidad and Tobago
<b>Dr Khaled Saeed</b>	Associate Professor, Institute of Psychiatry, Rawalpindi, Pakistan
<b>Dr Aive Sarjas</b>	Head, Department of Social Welfare, Ministry of Social Affairs of Estonia, Tallinn, Estonia
<b>Professor Shen Yucun</b>	Director, Institute of Mental Health, Beijing University, Beijing, China
<b>Dr Daya Somasundaram</b>	Department of Psychiatry, University of Jaffna, Sri Lanka

<b>Dr HWANG Tae-Yeon</b>	Director, Department of Psychiatric Rehabilitation and Community Mental Health, Yongin Mental Hospital, Kyonggi Province, Republic of Korea
<b>Dr Timi Tuori</b>	Ministry of Health and Population, Cairo, Egypt
<b>Ms Deborah Wan</b>	New Life Psychiatric Rehabilitation Association, Hong Kong, China
<b>Professor HAO Wei</b>	Mental Health Institute, Changsha, Hunan, China
<b>Dr Pude Yang</b>	Beijing Hui Long Guan Hospital, Beijing, China
<b>Dr ZOU Yizhuang</b>	Vice Director, Beijing Hui Long Guan Hospital, Beijing, China

In addition, WHO gratefully acknowledges the generous financial support of the Governments of Italy, the Netherlands and New Zealand.

*“Psychotropic medications are effective treatments for mental disorders when used in conjunction with psychosocial interventions. Attention to rational selection of drugs, affordability, sustainable financing and the availability of reliable health and supply systems will ensure that these treatments are available to those in need.”*

## Table of Contents

<b>Preface</b>	viii
<b>Executive summary</b>	2
<b>Aims and target audience</b>	6
<b>Abbreviations</b>	7
<b>1. Introduction</b>	<b>8</b>
<b>2. Improving access to psychotropics</b>	<b>12</b>
2.1 Making access an integral part of a mental health policy	13
2.2 Legislation supporting access	14
2.3 International trade agreements and access	15
2.4 Selecting the most needed psychotropics	16
2.5 Maximizing affordability of psychotropics	19
2.6 Ensuring sustainable financing	23
2.7 Improving distribution strategies and safeguarding quality	24
<b>3. Promoting appropriate use of psychotropics</b>	<b>26</b>
3.1 Factors underlying inappropriate use of medicines	26
3.2 Investigating the use of medicines	28
3.3 Improving the use of medicines	29
3.4 Examples of educational strategies	31
3.5 Examples of managerial strategies	32
3.6 Examples of regulatory strategies	33
3.7 Promoting appropriate use in the private sector	33
3.8 Making available unbiased information on medicines	34
<b>4. Assessing a psychotropic access system</b>	<b>36</b>
<b>5. A seven-step approach to improving access to psychotropics</b>	<b>41</b>
<b>Annex 1. Examples of treatment for disorders, including their pharmacological effectiveness</b>	<b>44</b>
<b>References</b>	<b>52</b>